ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2026
Is hemithyroidectomy enough? Low risk of occult contralateral disease in sporadic medullary thyroid cancer.
Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTotal thyroidectomy (TT) remains the standard surgical treatment of sporadic medullary thyroid cancer (sMTC), primarily due to the presumed risk of occult contralateral disease. However, recent evidence suggests that in selected patients, hemithyroidectomy (HT) may offer comparable oncologic outcomes. This retrospective study aimed to evaluate the prevalence of occult contralateral disease and to identify clinicopathological factors associated with disease-free survival (DFS).
methodsWe retrospectively analyzed all surgical patients with sMTC at a tertiary academic center (2013-2025), excluding patients with hereditary MTC, RET mutations, or clinical evidence of MEN2. Kaplan-Meier analysis with logrank testing was used to identify predictors of DFS.
resultsForty-eight patients were included (66.7% female, median age 60.5 years). TT was performed in 44 patients (91.7%). Bilateral disease was present in five patients (11.4%), all detected on preoperative ultrasound. No cases of occult contralateral disease were found. During a median follow-up of 3.4 years, seven patients (14.6%) experienced recurrence. Advanced T stage, nodal involvement, distant metastases, lymphatic and vascular invasion, extracapsular extension, and male sex were all significantly associated with reduced DFS (all p < 0.05). Persistent postoperative calcitonin elevation (> 2 pg/mL) strongly predicted recurrence (p < 0.001), whereas baseline calcitonin > 500 pg/mL did not.
conclusionOccult contralateral disease in sMTC is rare when high-quality preoperative ultrasound is available. In selected patients with unifocal, node-negative tumors and favorable pathology, HT combined with structured calcitonin monitoring may be an oncologically safe, less morbid alternative. These findings support individualized, risk-adapted surgical strategies in sMTC. Prospective validation is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.